Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs

Description

This study addresses real-world use of long-acting injectable cabotegravir/rilpivirine (CAB/RPV LA) by evaluating implementation and clinical outcomes of a pharmacist-led collaborative drug therapy management model (CDTM+) that will be expanded for telehealth outreach to women with health-related social needs (HRSN).

Conditions

Hiv

Talk to us

Study Overview

On this page

Study Details

Study overview

This study addresses real-world use of long-acting injectable cabotegravir/rilpivirine (CAB/RPV LA) by evaluating implementation and clinical outcomes of a pharmacist-led collaborative drug therapy management model (CDTM+) that will be expanded for telehealth outreach to women with health-related social needs (HRSN).

Project Tara: Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs

Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs

Condition
Hiv
Intervention / Treatment

-

Contacts and Locations

New Haven

Yale Clinical and Community Research, New Haven, Connecticut, United States, 06519

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Living with diagnosed HIV
  • * Receiving HIV care-related services from Yale New Haven Health (YNHH)
  • * Currently on oral ART and virally suppressed for at least 6 months (from electronic health review).
  • * Have experienced at least one HRSN: a) homelessness or housing insecurity; b) food insecurity; c) criminal legal system involvement; OR d) substance use in the past 6 months (from self-report at screening).
  • * Able to converse comfortably in English or Spanish
  • * Unable or unwilling to complete informed consent (e.g., have a conservator of person)
  • * Have initiated CAB/RPV oral lead-in prior to enrollment.
  • * Have a contraindication to CAB/RPV LA per label.
  • * Have known or suspected resistance to CAB/RPV
  • * Pregnant or breast-feeding

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Yale University,

Jaimie Meyer, MD, MS, FACP, PRINCIPAL_INVESTIGATOR, Yale School of Medicine

Study Record Dates

2025-05-30